BlueChew is not FDA approved. The medications sold through BlueChew are compounded versions of well-known erectile dysfunction drugs, and compounded drug products do not go through the standard FDA approval process. In September 2025, the FDA issued a warning letter to Dermacare LLC (the company operating as BlueChew), stating explicitly that “compounded drug products are not FDA-approved” and that the company’s marketing implied its products were equivalent to FDA-approved medications when they are not.
That said, the active ingredients inside BlueChew tablets have decades of FDA-approved history. The distinction between “FDA-approved ingredient” and “FDA-approved product” is where most of the confusion lives.
What BlueChew Actually Sells
BlueChew offers chewable tablets containing one of three active ingredients: sildenafil (the same ingredient in Viagra), tadalafil (Cialis), or vardenafil (Levitra). All three belong to a class of drugs called PDE5 inhibitors, which work by increasing blood flow to the penis during sexual stimulation. These ingredients have been used for erectile dysfunction for over two decades. Sildenafil was approved by the FDA in 1998, tadalafil and vardenafil both in 2003.
The key difference is that BlueChew’s tablets are made by a compounding pharmacy, not manufactured by the original pharmaceutical companies or their generic equivalents. Compounding pharmacies mix medications in custom formulations, in this case a chewable tablet rather than a standard pill you swallow whole. That compounded end product has never been submitted to or reviewed by the FDA for safety, effectiveness, or manufacturing consistency.
Why Compounded Drugs Skip FDA Approval
Compounding pharmacies operate under a different set of rules than large-scale drug manufacturers. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounded medication can be legally prepared without going through the full FDA approval process if it meets specific conditions. The drug must be compounded by a licensed pharmacist based on a valid prescription for an identified individual patient. The ingredients used must meet quality standards set by the United States Pharmacopoeia or be components of already-approved drugs. And the pharmacy cannot routinely produce large quantities of drugs that are essentially copies of commercially available products.
That last condition is where the FDA took issue with BlueChew. The agency’s warning letter pointed out that BlueChew’s sildenafil and tadalafil products are “new drugs” under federal law and are “not generally recognized as safe and effective for their labeled uses.” In practical terms, this means the FDA considers these compounded tablets to lack the same evidence package that backs an approved drug: controlled clinical trials, standardized manufacturing, and ongoing quality monitoring.
How This Affects Safety
The active ingredients themselves have a well-established safety profile. Side effects from PDE5 inhibitors occur in roughly 40% of users and are typically mild: headache, indigestion, nasal congestion, slight visual changes, muscle aches, dizziness, or a drop in blood pressure. These side effects are the same regardless of whether you take a brand-name pill, a generic, or a compounded chewable.
The safety concern specific to compounded medications is consistency. FDA-approved drugs must demonstrate that every batch contains the exact labeled dose and dissolves in the body the way clinical trials showed it would. Compounding pharmacies follow quality standards, but they aren’t subject to the same level of manufacturing oversight. This means there’s a small but real possibility of variation between batches in potency, absorption speed, or inactive ingredients that could affect how the drug works for you.
The serious risks of PDE5 inhibitors, compounded or not, come from drug interactions. These medications should never be combined with nitrate drugs (commonly prescribed for chest pain) because the combination can cause a dangerous drop in blood pressure. This is one reason a medical consultation is required before you can get a prescription.
BlueChew’s Prescription Process
BlueChew requires an online medical consultation before dispensing medication. You fill out a health questionnaire, and a licensed provider reviews it to determine whether a PDE5 inhibitor is appropriate for you. If approved, they write a prescription that the compounding pharmacy fills. This telemedicine model is legal under current federal rules, which allow practitioners to prescribe medications, including controlled substances, through telehealth visits without an in-person exam through at least the end of 2026.
The prescription step is legitimate and mirrors what happens at a doctor’s office. What you receive after that prescription, however, is a compounded product rather than an FDA-approved one.
FDA-Approved Chewable Alternatives Now Exist
For anyone specifically wanting a chewable erectile dysfunction tablet with full FDA backing, there is now an option. In June 2024, the FDA approved Chewtadzy, a chewable tadalafil tablet available in 5, 10, and 20 mg strengths. It’s distributed by ANI Pharmaceuticals and went through the complete FDA approval process, meaning its manufacturing, dosing, and performance have been formally reviewed. If the lack of FDA approval on BlueChew’s products concerns you, this is the closest equivalent that carries that regulatory stamp.
Sildenafil does not yet have an FDA-approved chewable version, so if you prefer that ingredient in a chewable form, compounded products like BlueChew remain the primary option.
The Bottom Line on Regulatory Status
BlueChew’s products contain ingredients that are FDA approved, sold in a formulation that is not. The ingredients have strong clinical evidence behind them. The compounded chewable tablets have not been independently evaluated by the FDA for quality, safety, or effectiveness. Whether that distinction matters to you depends on how much weight you place on manufacturing oversight versus the convenience and cost of a compounded product. The FDA has made its position clear: these are not the same as approved medications, and marketing them as if they were is a problem.